Showing results (431-440 of 481) with videos related to

Sort By:
Pageof 49
Blood Advances|April 26, 2024
Defining primary refractory large B-cell lymphomaAllison M Bock, Raphael Mwangi, Yucai Wang, et al.
Blood|July 22, 2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Rizwan Romee, Andrew St Martin, et al.
Transplantation and Cellular Therapy|December 28, 2022
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host DiseaseChenyu Lin, Rachel A DiCioccio, Tarek Haykal, et al.
Atherosclerosis|September 26, 2006
LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesionsPaulo I Homem de Bittencourt, Denise J Lagranha, Alexandre Maslinkiewicz, et al.
Transplantation and Cellular Therapy|September 23, 2020
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular TherapyBhagirathbhai Dholaria, Bipin N Savani, Betty K Hamilton, et al.
Blood|September 5, 2021
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AMLFei Yang, Nicola Long, Tauangtham Anekpuritanang, et al.
Science (New York, N.Y.)|February 22, 2020
Old carbon reservoirs were not important in the deglacial methane budgetM N Dyonisius, V V Petrenko, A M Smith, et al.
Hematological Oncology|November 29, 2024
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment ResistanceAllison M Bock, Kerstin Wenzl, Joseph P Novak, et al.
Blood Cancer Journal|July 12, 2025
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphomaJanek S Walker, Kerstin Wenzl, Joseph P Novak, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Pageof 49